Early anti-PD-1 data from Merck and Bristol-Myers Squibb will help show if hematology is as promising as solid tumors

Wall Street will also be looking at early indications of efficacy in hematological cancer for anti-PD-1s. Much of the early PD-1 data has been in solid tumors, rather than hematology.


 

 

While one investor--whose firm requires him to remain unnamed--said he expects anti-PD-1s to be more about solid tumors than hematology, he does expect that, within hematology, anti-PD1s could be a significant hematology focus.

Oliver Marti of Columbus Circle Investors expects PD-1 data to continue to be mixed in non-Hodgkin lymphoma, but weak in multiple myeloma.

Merck ($MRK) will present data for its anti-PD-1 Keytruda in relapsed/refractory classical Hodgkin lymphoma at ASH, while Bristol-Myers Squibb ($BMY) will have non-Hodgkin lymphoma and lymphoid malignancy data for its Opdivo.

"ASH will provide initial data on BMY's and Merck's PD-1 inhibitors Opdivo and Keytruda in hematologic malignancies. Opdivo achieved an impressive 87% objective response rate in heavily pretreated patients with Hodgkin's lymphoma. Keytruda preliminary results look a bit weaker than Opdivo's. However, follow-up was shorter in the Keytruda study (KEYNOTE-13)," noted Mario Linimeier of investment firm Medical Strategy.

For more:
Five Prime hitches onto Bristol-Myers' blockbuster-in-waiting immunotherapy
Bristol-Myers' oncology star lines up for lung cancer approval, leading the PD-1 pack
Merck takes to Europe with its promising PD-1 cancer drug

Early anti-PD-1 data from Merck and Bristol-Myers Squibb will help show if hematology is as promising as solid tumors
Read more on

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.